Abstract. Psoriatic arthritis (PsA) is an inflammatory potentially destructive disease that requires early diagnosis and therapeutic approach. Its main pathogenic event and the condition’s hallmark is considered to be enthesitis. Clinical examination of the enthesis can be a challenge in the clinical practice; thus, ultrasonography (US) has emerged as an indispensable imaging tool for evaluating both structural and inflammatory changes of this structure. In the present study, we aimed to analyze the type and frequency of entheseal involvement in PsA patients by US examination, performing a retrospective study on 41 patients diagnosed with PsA. Ultrasonographically confirmed enthesitis, identified according to Outcome Measures in Rheumatology group (OMERACT, initially Outcome Measures in Rheumatoid Arthritis Clinical Trials) definitions, was present in 26 of the included patients, Achilles enthesis being the most common site involved. The prevalence of tendon structure abnormalities and the presence of enthesophytes underlines the importance of chronic inflammation on entheseal sites. US examination has proven to be a reliable imaging method, with significant and continuous improvement, which is clearly a requisite part for current understanding and diagnosis of enthesitis and more than this, for the patient follow-up algorithm.

Introduction

Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease that occurs in ~30% of patients with psoriasis. Although the diagnosis of arthritis is usually established years after skin involvement, the joint involvement sometimes can precede it, with peripheral arthritis, as well as spine inflammatory changes (1-4). Enthesitis, inflammation of the origin and insertion of ligaments, tendons, aponeuroses, annulus fibrosis and joint capsules, has been suggested to be the underlying feature of PsA and it is reported to be present in 30-50% of the cases (5,6). In PsA, as stated by the Classification Criteria for Psoriatic Arthritis (CASPAR) as well as by the Group for Research and Assessment of Psoriasis and Psoriatic arthritis (GRAPPA) recommendations, enthesitis identification is useful for diagnosis and treatment (7,8).

Clinical examination of enthesis can be a challenge in clinical practice, as its presentation can vary from asymptomatic to inflammatory, mechanical or traumatic type of involvement. Thus, it is highly necessary to use imaging techniques, such as magnetic resonance imaging (MRI) or ultrasonography (US), in order to properly detect the type and nature of the changes. US has emerged as an indispensable tool for evaluating all types of rheumatic conditions, offering the advantage of being non-invasive, reproducible and easily to be used by an experienced examiner (9-12). In PsA patients, US seems to have a higher importance compared to MRI, as it is more accurate in describing the structure, new bone formation or vascularization and at a higher detail (13-15). Several scores have been proposed in order to evaluate the extent of enthesal

Correspondence to: Professor Florentin Ananu Vreju, Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares Street, 200349 Craiova, Romania
E-mail: florin_vreju@yahoo.com

Dr Mihail Virgil Boldeanu, Department of Immunology, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares Street, 200349 Craiova, Romania
E-mail: boldeanumihailvirgil@yahoo.com

*Contributed equally

Key words: psoriatic arthritis, enthesitis, inflammation, ultrasonography, Achilles tendon
abnormalities, among which is the MAdrid Sonographic Enthesis Index (MASEI), which has proven to be a reliable tool in detecting signs of both subclinical and constituted disease (13,16).

The present study aimed to analyze the type and frequency of entheseal involvement in PsA patients, by US examination, using MASEI and OMERACT definitions, as well as a search for correlations between the presence of enthesitis and a series of disease variables. The aim of our study was to provide a possible pattern of involvement for enthesis in PsA patients, in order to optimize the management of these patients.

**Patients and methods**

We performed a retrospective study on 41 patients diagnosed with PsA based on CASPAR criteria (7), in a one-year interval between 2018 and 2019, admitted into the Rheumatology Department of the Emergency County Hospital Craiova, Romania. We collected data that included demographic, clinical, laboratory parameters and imagistic methods, in accordance to the study protocol.

The study was performed in accordance with the ethics and deontology principles of the Helsinki Human Right's
Declaration and was approved by the Emergency County Hospital Craiova Ethics Committee (under the number of 28690/2019). Written informed consent was obtained from each patient.

US. The examination was performed by an expert sonographer (FAV), blinded to the history, clinical findings, and biology of each patient, using an Esaote MyLab 25 machine, equipped with a high frequency linear probe (10-18 MHz). Enthesitis was evaluated and defined according to OMERACT (Outcome Measures in Rheumatology) definitions (17). The MASEI items were evaluated according to the description (16) (Table I).

Statistical analysis. Statistical analysis was performed using GraphPad Prism 5.5 (GraphPad Software, Inc.). Results are presented as mean ± SD and data were analyzed using t-test and one-way ANOVA for comparing groups, and Pearson/Spearman's coefficient for evaluating correlations. We considered a level of P<0.05 statistically significant.

Results

We included 41 consecutive patients, 27 women and 14 men, with a mean age of 53.44±0.91 years and a mean disease duration of 6.63±4.26 years, ranging from 0.5 to 12 years. We registered a mean body mass index (BMI) of 27.44±6.35 [11 (26.82%) patients were overweight and 13 (31.70%) obese]. The general characteristics of the study group are presented in Table II.

In regard to inflammatory markers, we found a mean value of 11.66±26.6 mg/dl for C reactive protein (CRP) and 33.27±25.59 for erythrocyte sedimentation rate (ESR).

Synthetic disease-modifying anti-rheumatic drugs (DMARDs) were a therapeutic option for all the patients and biologic DMARD for 39.02% (16 patients).

In regards to scoring the disease activity, we found a mean disease activity in the Disease Activity Index for Psoriatic Arthritis (DAPSA) score of 11.80±4.91, with limits between 2 and 25.8. For the Psoriasis Area Severity Index (PASI), we registered values between 0 and 28, with a mean of 15.32±7.12.

Enthesitis, according to OMERACT definitions, was present in 26 of the included patients (63.41%). We identified Achilles enthesis (AT) as the most common site [19 (46.34%)], followed by distal patellar tendon (DP) [11 (26.82%)], quadriceps tendon (QT) [11 (26.82%)], proximal patellar tendon (PP) [9 (21.94%)] and plantar aponeurosis (PA) [9 (21.94%)] (Table III, Figs. 1-3). Given the fact that all patients received DMARD therapy, synthetic with/without biologic, the US evaluation of our study group did not show a high percentage of active Power Doppler (PD) enthesitis in the evaluated sites, except AT (24.32%) (Table III, Fig. 2).

We carried out further statistical analysis on the possible correlations between the presence of enthesitis and certain variables. We found a moderately positive correlation between the presence of enthesitis and inflammatory markers (r=0.42, P=0.005 for CRP and r=0.56, P=0.020 for ESR). Another significant correlation was established between US enthesitis, patient age (r=0.37, P=0.05) and PASI score (r=0.43, P=0.004).

Of the 18 patients with a moderate/severe PASI score, 13 had enthesial involvement at US evaluation.

When we analyzed our data for the effect of body mass index (BMI) on enthesial damage, although the value of Pearson correlation coefficient was 0.35, we noted that US examination found a high percentage of enthesitis in overweight and obese

| Patients (N) | Data values |
|-------------|-------------|
| Female, n (%) | 27 (65.86) |
| Male, n (%) | 14 (34.14) |
| Mean age (years) | 54.34±0.91 |
| Disease duration (years) | 6.63±4.26 |
| Type of psoriasis, n (%) |  |
| Nail | 24 (58.53) |
| Skin | 35 (85.36) |
| Nail and skin | 24 (58.53) |
| Sine psoriasis | 5 (12.19) |
| Type of psoriatic arthritis, n (%) |  |
| Peripheral | 32 (78.04) |
| Axial and peripheral | 9 (21.95) |
| CRP (mg/dl) | 11.66±26.60 |
| ESR (mm/h) | 32.27±25.59 |
| DAPSA | 11.80±4.91 |
| PASI | 15.32±7.12 |
| BMI (kg/m²) | 27.44±6.35 |
| Uric acid (mg/dl) | 4.77±1.48 |
| Current medication, n (%) |  |
| DMARD non-biologic | 41 (100) |
| DMARD biologic | 16 (39.02%) |
| MASEI score (mean ± SD) | 13.2±5.8 |

CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DAPSA, Disease Activity Index for Psoriatic Arthritis; PASI, Psoriasis Area Severity Index; BMI, body mass index; DMARD, disease-modifying anti-rheumatic drug; MASEI, Madrid Sonography Enthesitis Index.
PsA is a disease that requires early diagnosis and therapeutic approach in order to prevent future tendon and articular damage and its consequent functional impairment. Enthesal involvement is a hallmark of the disease, more commonly found in PsA patients compared to other inflammatory or non-inflammatory conditions, directly related to both peripheral and axial structural damage (1). Clinical examination can be challenging in identifying enthesitis, both for asymptomatic patients as for those presenting signs and symptoms similar to other conditions and often requires additional imaging techniques (18).

US is a well-established validated method for detecting enthesitis (19), both subclinical and clinical manifestations, in patients with PsA and psoriasis, providing an accurate information on both structural and inflammatory changes. Moreover, it has been reported to be a real-time, reproducible, and cost-effective technique. Several previous studies, which have focused on enthesis evaluation in PsA patients, have proven that this condition is particularly known to be an entheseal disease, with significant impact on disease activity and quality of life. In order to obtain a proper indicator of disease activity and treatment response, patient evaluation should mandatorily include US entheseal assessment (7,15-18).

The involvement of US entheseal in PsA patients, as aimed by our research, revealed it to be present in a high percentage of patients. The data found in our study (63.41%) is similar to data reported by Gutierrez et al, in a study conducted on patients (16 of 22, compared to 10 of the 19 patients with a normal BMI).

### Discussion

PsA is a disease that requires early diagnosis and therapeutic approach in order to prevent future tendon and articular damage and its consequent functional impairment. Enthesal involvement is a hallmark of the disease, more commonly found in PsA patients compared to other inflammatory or non-inflammatory conditions, directly related to both peripheral and axial structural damage (1). Clinical examination can be challenging in identifying enthesitis, both for asymptomatic patients as for those presenting signs and symptoms similar to other conditions and often requires additional imaging techniques (18).

US is a well-established validated method for detecting enthesitis (19), both subclinical and clinical manifestations, in patients with PsA and psoriasis, providing an accurate information on both structural and inflammatory changes. Moreover, it has been reported to be a real-time, reproducible, and cost-effective technique. Several previous studies, which have focused on enthesis evaluation in PsA patients, have proven that this condition is particularly known to be an entheseal disease, with significant impact on disease activity and quality of life. In order to obtain a proper indicator of disease activity and treatment response, patient evaluation should mandatorily include US entheseal assessment (7,15-18).

The involvement of US entheseal in PsA patients, as aimed by our research, revealed it to be present in a high percentage of patients. The data found in our study (63.41%) is similar to data reported by Gutierrez et al, in a study conducted on patients (16 of 22, compared to 10 of the 19 patients with a normal BMI).

### Table III. Ultrasonography (US) changes according to MASEI.

|                  | Abnormal tendon structure n (%) | Thickened tendon n (%) | Erosion n (%) | Enthesis calcification/ enthesophyte n (%) | Enthesis PD n (%) | Bursitis n (%) |
|------------------|---------------------------------|------------------------|--------------|------------------------------------------|------------------|---------------|
| TT               | 2 (4.87)                        | 1 (2.43)               | 0            | 4 (9.75)                                 | 0                | 0             |
| QT               | 8 (19.51)                       | 3 (7.31)               | 1 (2.43)     | 7 (17.07)                                | 3 (7.31)         | 0             |
| PP               | 5 (12.19)                       | 4 (9.75)               | 1 (2.43)     | 3 (7.31)                                 | 1 (2.43)         | 0             |
| DP               | 6 (14.63)                       | 5 (12.19)              | 0            | 2 (4.87)                                 | 2 (4.87)         | 0             |
| AT               | 12 (29.26)                      | 7 (17.07)              | 6 (14.63)    | 7 (17.07)                                | 10 (24.39)       | 2 (4.87)      |
| PA               | 6 (14.63)                       | 3 (7.31)               | 2.43         | 9.75                                     | 0                | 0             |

MASEI, Madrid Sonography Enthesitis Index; TT, tibial tuberosity; QT, quadriceps tendon; PP, proximal patellar tendon; DP, distal patellar tendon; AT, Achilles tendon; PA, plantar aponeurosis. Enthesis PD was defined as the presence of Power Doppler signal, within the enthesis, at less than 2 mm from the bone cortical. Bursitis was defined as the presence of a hypoechoic/anechoic area at the level of a specific bursa.

---

**Figure 2.** Grey scale US of Achilles tendon. (A) Longitudinal and (B) transverse scan: Hypoechoic Achilles tendon (AT), with loss of the fibrillar pattern, mostly near to the cortical calcaneus (C in the images) bone (<2 mm), findings suggestive for enthesitis. Moreover, we observed erosion (arrow), like step-down changes, identified in two perpendicular views. US, ultrasonography; AT, Achilles tendon; C, calcaneus (Esaote, MyLab25 18 MHz).

**Figure 3.** Power Doppler US image of the patellar tendon's distal enthesis, revealing a hypoechoic tendon, with a homogenous fibrillar pattern (arrow), mostly near to the cortical bone (<2 mm), with intense power Doppler signal. US, ultrasonography; T, tibial tuberosity; DP, distal patellar tendon (Esaote, MyLab25 18 MHz).
45 patients (20). Other publications have also demonstrated similar data (1,21-24).

The prevalence of tendon structure abnormalities and enthesophytes as reported by significant scientific reports is similar to our results, underlying the importance of chronic inflammation on enthesial sites (1,21).

The most common site of inflammation found in our patients was represented by Achilles enthesis. Michelsen et al assessed 141 patients and revealed percentages of over 50 for structural damage and 16.3 for inflammatory activity, when examining AT, similar to our results (25). The observation made by the aforementioned study, that AT insertion is the site of major enthesial abnormalities, was also confirmed by Perrotta et al (26). A recent multi-center study, that enrolled a total number of 1,130 PsA patients, reported that 22.2% presented with active enthesitis (27).

The observation that the PASI score was correlated with enthesitis is in full agreement with the report of Moshrif et al (21), as well as with other studies (28,29).

Analyzing the associations between different variables and the presence of enthesitis, we observed a moderately positive correlation with body mass index (BMI). Although the calculated Pearson correlation coefficient was 0.35, overweight and obese patients presented a higher prevalence of enthesial abnormalities. BMI, a variable with significant role in enthesial findings, is generally higher in PsA patients, compared to healthy subjects. The mean BMI calculated for our group was 27.4±6.35. US scores, such as MASEI, and more specifically AT abnormalities and enthesophytes presence, were demonstrated to be positively correlated to an increased BMI (1,30-33). In our study group, we also obtained a moderately positive inter-relationship between the two variables. Nevertheless, BMI is also a factor of biomechanical stress, which can input certain abnormalities of this structure.

The lack of Doppler activity in our patients may have been related as already mentioned to the fact that most patients were already receiving disease-modifying anti-rheumatic drug (DMARD) treatment, but, at the same time, we realized the fact that the machine's sensitivity on vascularization might have influenced the results. Other limitations of the study include the small number of patients and the fact that we had only one US examiner and no other imaging technique was used to confirm the findings.

In conclusion, enthesitis, the defining feature of PsA and an important part of the disease pathogenesis, predicts patient outcome, future structural changes and noticeably impacts the quality of life of these patients. US examination has proven to be a reliable imaging method, with significant and continuous improvement, which is clearly a requisite part of the current understanding and diagnosis of enthesitis and patient follow-up algorithm.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

BAC, ALB, RMD and FAV conceived and designed the current study. BAC, ALB, CDP, SCF and SCD provided administrative support. BAC, ALB, CDP, SCF, RMD, SBC, MV, SCD, HVP, RAI, ATS, AMV and FAV searched the literature for pertinent data and findings. BAC, CDP, SCF, RMD, SBC, SCD, AMV and FAV collected and collated the data. BAC, CDP, SCF, RMD, SBC, PLC, SCD, MV, HVP, RAI, ATS and FAV analyzed and interpreted the data. All authors wrote the manuscript and all authors read and approved the final manuscript for publication.

Ethics approval and consent to participate

The study complied with the Declaration of Helsinki and was approved by the Emergency County Hospital Craiova Ethics Committee (under the number of 28690/2019). Written informed consent was obtained from each patient.

Patient consent for publication

The patients consented to the publication of their data and images in the present study.

Competing interests

The authors declare that they have no competing interests.

References

1. Kaeley GS, Eder L, Aydin SZ, Gutierrez M and Bakewell C: Enthesitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum 48: 35-43, 2018.
2. Mease PJ, Gladman DD, Papp KA, Kharesh MM, Thaci D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R and Alvarez D: Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 69: 729-735, 2013.
3. Catanoso M, Pipitone N and Salvarani C: Epidemiology of psoriatic arthritis. Reumatismo 64: 66-70, 2012.
4. Chisălău BA, Cringus LI, Vreju FA, Părăvănescu CD, Firulescu SC, Dinescu ȘC, Ciobanu DA, Tica AA, Sandu RE, Siloși I, et al: New insights into IL-17/IL-23 signaling in ankylosing spondylitis (Review). Exp Ther Med 20: 3493-3497, 2020.
5. Gladman DD: Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am 41: 569-579, 2015.
6. Polachek A, Li S, Chandran V and Gladman D: Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: Incidence, prevalence, characteristics and outcome. Arthritis Care Res (Hoboken) 69: 1685-1691, 2016.
7. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P and Mielants H; CASPAR Study Group: Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 54: 2665-2673, 2006.
8. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer L, Armstrong M, Bautista-Molano AW, Boehncke W, Campbell WH, Cauil W, et al: Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68: 1060-1071, 2016.
9. Barbulescu AL, Ciurea PL, Mitran C, Chisalau BA, Parvanescu CD, Firulescu SC, Balascou M, Boldeanu MV, Popoviciu H and Veju FA: High frequency ultrasonography of the hand versus anti-RA33 evaluation in early rheumatoid arthritis-a pilot study. Med Ultrason 19: 166-171, 2017.
10. Veju FA, Ciurea ME, Popa D, Popa F, Parvanescu CD, Chisalau BA, Barbulessu AL, Parvanescu V, Rosu A and Ciurea PL: Ultrasonography in the diagnosis and monitoring of noninflammatory conditions of the hand and wrist. Med Ultrason 18: 90-95, 2016.
11. Ciurea ME, Ciurea RN, Bârdulescu AL, Chisalău A, Pârvănescu CD, Firulescu SC, Covâ Bânciuciu S, Ciurea PL and Veju AF: Intramuscular heman gioma of the arm: Ultrasonography and pathology findings. Rom J Morph Embryol 57: 521-524, 2016.
12. Filippou G, Scirè CA, Adinolfi A, Damjanov NS, Carrara G, Bruyn GW, Cazenave T, D'Agostino MA, Delle Sedie A, Di Sabatino V, et al: Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasonography: Reliability of the OMERACT definitions in an extended set of joints-an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force. Ann Rheum Dis 77: 1194-1199, 2018.
13. De Miguel E, Cobo T, Munoz-Fernandez S, Naredo E, Uson J, Acebes JC and Martin-Mola E: Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 68: 169-174, 2009.
14. Micu MC and Fodor D: Concepts in monitoring enthesitis in psoriatic arthritis. Ann Rheum Dis 77: 1194-1199, 2018.
15. Poggenborg RP, Eshed I, Östergaard M, Sorensen TI, Møller JM, Madsen OR and Pdersen SJ: Enthesitis in patients with psoriatic arthritis, axial spondylarthropathy and healthy subjects assessed by ‘head-to-toe’ whole-body MRI and clinical examination. Ann Rheum Dis 74: 823-829, 2015.
16. Wervers K, Vis M, Rasappu N, Van Der Ven M, Thetverikov I, Kok MR, Gerards AH, Hazes J and Luime JJ: Modification of a sonographic enthesis score to differentiate between psoriatic arthritis and young healthy volunteers. Scand J Rheumatol 47: 291-294, 2018.
17. Balint PV, Terslev L, Aegerter P, Bruyn AWG, Chary-Valkenaere I, Gandjbakhch F, Iagnocco AM, Jousse-Joulin SJ, Möller I, Naredo E, et al: On behalf of the Omeract ultrasound task force members, reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthropathy and psoriatic arthritis: An OMERACT US initiative. Ann Rheum Dis 77: 1730-1735, 2018.
18. Zabotti A, Bandinelli F, Batticciotto A, Scirè CA, Iagnocco A and Sakellariou G: Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: A systematic literature review. Rheumatology 56: 1518-1532, 2017.
19. Gandjbakhch F, Terslev L, Joshua F, Wakefield RJ, Naredo E, D'Agostino MA; OMERACT Ultrasound Task Force: Ultrasonography in the evaluation of enthesitis: Status and perspectives. Arthritis Res Ther 13: R188, 2011.
20. Gutierrez M, Filippucci E, De Angelis R, Salaffi F, Filosa G, Ruta S, Bertolazzi C and Grassi W: Subclinical enthesal involvement in patients with psoriasis: An ultrasound study. Semin Arthritis Rheum 40: 407-412, 2011.
21. Moshirif A, Mosallam A, Mohamed EEM, Gouda W and Doma M: Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: A power Doppler ultrasonography study. Eur J Rheumatol 4: 24-28, 2017.
22. Naredo E, Möller I, De Miguel E, Batlle-Gualda E, Acebes C, Brito E, Mayordomo L, Moragues C, Uson J, De Agustín JJ, et al: High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: A prospective case-control study. Rheumatology (Oxford) 50: 1838-1841, 2011.
23. Eder L, Barzilai M, Peled N, Gladman DD and Zisman D: The use of ultrasound for the assessment of enthesis in patients with spondyloarthritis. Clin Radiol 68: 219-223, 2013.
24. Kristensen S, Christensen JH, Schmidt EB, Olesen JL, Johansen MB, Arvesen KB and Schlemmer A: Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound. Muscles Ligaments Tendons J 6: 241-247, 2016.
25. Michelsen B, Diamantopoulos AP, Soldal DM, Hammer HB, Kavanagh A and Haugeberg G: Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. RMD Open 3: e000486, 2017.
26. Perrotta FM, Astorri D, Zappia M, Reginelli A, Brunese L and Lubrano E: An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment. Rheumatol Int 36: 1579-1583, 2016.
27. Sunar I, Ataman S, Nas K, Kilic E, Sargin B, Kasman SA, Alkan H, Sahin N, Cengiz G, Cuzdan N, et al: Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: A multi-center study. Rheumatol Int 40: 283-294, 2020.
28. Sakkas LI, Alexiou I, Simopoulou T and Vlychou M: Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 43: 325-334, 2013.
29. Husic R, Anja Ficjan A, Christina Duftner C and Dejaco C: Use of ultrasound for diagnosis and follow-up of psoriatic arthritis. EMJ Rheumatol 1: 65-72, 2014.
30. Grisendi P, Tinazzi I, El-Dalati G, Gallo M, Biasi D, Barbara LM and Vreju AF: High frequency ultrasonography of noninflammatory conditions of the hand and wrist. Med Ultrason 19: 166-171, 2017.
31. Popoviciu H and Vreju FA: Intramuscular hemangioma of the arm: Ultrasound and pathology findings. Rom J Morph Embryol 57: 521-524, 2016.